CN1216051C
(en)
*
|
1998-06-17 |
2005-08-24 |
卫材株式会社 |
Macrocyclic analogs and methods of their use and preparation
|
US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
US6653341B1
(en)
*
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
DE10037310A1
(en)
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
New indole derivatives and their use as medicines
|
WO2003072754A2
(en)
*
|
2002-02-27 |
2003-09-04 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
|
RU2342399C2
(en)
|
2002-03-22 |
2008-12-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Hemiasterlyn derivatives and application thereof for at cancer treatment
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
MXPA05012814A
(en)
*
|
2003-05-29 |
2007-01-25 |
Abbott Lab |
Continuous dosing regimen with abt-751.
|
WO2005011589A2
(en)
*
|
2003-07-29 |
2005-02-10 |
Eisai Co., Ltd. |
Drug delivery methods and devices
|
EP2949652B1
(en)
|
2004-06-03 |
2019-08-07 |
Eisai R&D Management Co., Ltd. |
Intermediates for the preparation of halichondrin B
|
CN1993342A
(en)
*
|
2004-06-03 |
2007-07-04 |
卫材株式会社 |
Intermediates for the preparation of halichondrin b
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
EP1831697A4
(en)
*
|
2004-12-09 |
2011-01-26 |
Eisai R&D Man Co Ltd |
Tubulin isotype screening in cancer therapy using halichondrin b analogs
|
MX2010003599A
(en)
|
2007-10-03 |
2010-09-10 |
Eisai R&D Man Co Ltd |
Intermediates and methods for the synthesis of halichondrin b analogs.
|
US8598373B2
(en)
|
2008-04-04 |
2013-12-03 |
Eisai R&D Management Co., Ltd. |
Halichondrin B analogs
|
RU2476216C1
(en)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Liposomal composition
|
JP5622719B2
(en)
|
2009-03-30 |
2014-11-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Method for producing liposome composition
|
LT2415470T
(en)
|
2009-03-30 |
2016-10-10 |
Eisai R&D Management Co., Ltd. |
Liposome composition
|
US8765974B2
(en)
*
|
2009-04-14 |
2014-07-01 |
Nissan Chemical Industries, Ltd. |
Method for producing tetrahydropyran compound and intermediate thereof
|
CA2787919C
(en)
|
2010-01-26 |
2018-07-31 |
Eisai R&D Management Co., Ltd. |
Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
|
SG10201602147YA
(en)
|
2011-03-18 |
2016-05-30 |
Eisai R&D Man Co Ltd |
Methods And Compositions For Predicting Response To Eribulin
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
ES2841809T3
(en)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarkers to predict and evaluate the degree of response of subjects with thyroid and kidney cancer to lenvatinib compounds
|
EP2785687B1
(en)
|
2011-11-30 |
2019-02-20 |
Sandoz AG |
Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
|
AU2012350420A1
(en)
|
2011-12-16 |
2014-07-10 |
Alphora Research Inc. |
Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
|
SI2797945T1
(en)
*
|
2011-12-29 |
2016-07-29 |
Alphora Research Inc. |
2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
|
IN2014MN02106A
(en)
*
|
2012-03-30 |
2015-09-11 |
Alphora Res Inc |
|
RU2689977C2
(en)
|
2012-12-04 |
2019-05-30 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Using eribulin for treating breast cancer
|
CA2909209A1
(en)
|
2013-05-15 |
2014-11-20 |
Alphora Research Inc. |
3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
|
BR112015029386B1
(en)
|
2013-06-26 |
2023-11-14 |
Eisai R&D Management Co., Ltd. |
USE OF ERIBULIN AND LENVATINIB AS COMBINATION THERAPY AND KIT
|
WO2015000070A1
(en)
|
2013-07-03 |
2015-01-08 |
Alphora Research Inc. |
Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
|
CN103483352A
(en)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
Medicinal bulk drug for resisting tumors
|
US9783549B2
(en)
|
2013-11-04 |
2017-10-10 |
Eisai R&D Management Co., Ltd. |
Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B
|
MX370611B
(en)
|
2013-12-06 |
2019-12-18 |
Eisai R&D Man Co Ltd |
Methods useful in the synthesis of halichondrin b analogs.
|
CN104860978A
(en)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
Synthesis intermediates of halichondrin B analog
|
TW201617326A
(en)
*
|
2014-03-06 |
2016-05-16 |
Alphora研發股份有限公司 |
Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
|
US20170100367A1
(en)
|
2014-05-28 |
2017-04-13 |
Eisai R&D Management Co., Ltd. |
Use of eribulin in the treatment of cancer
|
JP2017520586A
(en)
|
2014-06-30 |
2017-07-27 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Synthesis and use of halichondrin analogues
|
KR102512940B1
(en)
|
2014-08-28 |
2023-03-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
High-purity quinoline derivative and method for manufacturing same
|
WO2016038624A1
(en)
|
2014-09-09 |
2016-03-17 |
Cipla Limited |
"process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
|
CN105713031B
(en)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
Intermediate for preparing eribulin and preparation method thereof
|
CA2976325C
(en)
|
2015-02-25 |
2023-07-04 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
KR102662228B1
(en)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer
|
AU2016226157B2
(en)
|
2015-03-04 |
2022-01-27 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and eribulin for treating cancer
|
WO2016176560A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
KR20180013943A
(en)
*
|
2015-05-07 |
2018-02-07 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halicondrine markrolides
|
US10597401B2
(en)
|
2015-05-08 |
2020-03-24 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
BR112017027227B1
(en)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
ANTI-CANCER AGENT
|
KR20180107243A
(en)
*
|
2016-02-12 |
2018-10-01 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Intermediates and related synthetic methods in the synthesis of eribulin
|
EP3449921B1
(en)
|
2016-04-28 |
2023-05-31 |
Eisai R&D Management Co., Ltd. |
Eribulin for inhibiting tumor growth
|
CN109415383A
(en)
*
|
2016-05-26 |
2019-03-01 |
雷迪博士实验室有限公司 |
Prepare the method and its intermediate of eribulin
|
MX2018016329A
(en)
|
2016-06-30 |
2019-09-18 |
Eisai R&D Man Co Ltd |
Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof.
|
WO2018071792A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
JP6978758B2
(en)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Palladium-mediated ketolization
|
WO2018096478A2
(en)
|
2016-11-23 |
2018-05-31 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
KR101991710B1
(en)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
Intermediate for Preparing Eribulin Mesylate and Process for Preparing the Same
|
KR101880939B1
(en)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
Intermediate for Preparing Eribulin Mesylate and Process for Preapring the Same
|
CN110139866B
(en)
*
|
2017-01-02 |
2022-05-17 |
研成精密化学株式会社 |
Intermediate for preparing eribulin mesylate and method for preparing same
|
CN108341828B
(en)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
Process for the preparation of eribulin and intermediates thereof
|
CN108341738B
(en)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
Process for the preparation of eribulin and intermediates thereof
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
MD3606928T2
(en)
|
2017-04-05 |
2022-12-31 |
Harvard College |
Macrocyclic compound and uses thereof
|
CA3211559A1
(en)
|
2017-07-06 |
2019-01-10 |
President And Fellows Of Harvard College |
Synthesis of halichondrins
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
CN109694379B
(en)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
Intermediate for preparing eribulin and preparation method thereof
|
CN111328328B
(en)
*
|
2017-11-09 |
2023-05-23 |
研成精密化学株式会社 |
Intermediate for preparing eribulin mesylate and preparation method thereof
|
CN117924310A
(en)
|
2017-11-15 |
2024-04-26 |
哈佛大学的校长及成员们 |
Macrocyclic compounds and uses thereof
|
US11419856B2
(en)
|
2017-11-20 |
2022-08-23 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
WO2019102490A1
(en)
|
2017-11-21 |
2019-05-31 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
JP7469226B2
(en)
|
2018-01-03 |
2024-04-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
The Prins reaction and compounds useful for the synthesis of halichondrin macrolides and their analogues
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
EP3823973A4
(en)
*
|
2018-07-20 |
2022-09-21 |
Dr. Reddy's Laboratories Limited |
Purification process for preparation of eribulin and intermediates thereof
|
WO2020075027A1
(en)
*
|
2018-10-09 |
2020-04-16 |
Dr. Reddy's Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
WO2020255164A1
(en)
|
2019-06-21 |
2020-12-24 |
Council Of Scientific And Industrial Research |
A chemo-enzymatic process for the preparation of homopropargylic alcohol
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
MX2022005221A
(en)
|
2019-11-07 |
2022-06-08 |
Eisai R&D Man Co Ltd |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use.
|
CN113135876B
(en)
*
|
2020-01-16 |
2024-05-17 |
南通诺泰生物医药技术有限公司 |
Preparation method of eribulin and intermediate thereof
|
WO2021148003A1
(en)
*
|
2020-01-22 |
2021-07-29 |
上海森辉医药有限公司 |
Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
|
KR102377262B1
(en)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
Crystalline Eribulin Salt
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
Process for the preparation of eribulin
|
CN113354659B
(en)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
Synthesis of eribulin mesylate
|
CA3225975A1
(en)
*
|
2021-07-22 |
2023-01-26 |
Shanghai Senhui Medicine Co., Ltd. |
Drug conjugate of eribulin derivative
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|
WO2024153123A1
(en)
*
|
2023-01-17 |
2024-07-25 |
成都百利多特生物药业有限责任公司 |
Conjugate of eribulin drug
|